Laboratory aspects of von Willebrand disease : test repertoire and options for activity assays and genetic analysis
(2014) In Haemophilia 20. p.65-70- Abstract
The deficiency or abnormal function of von Willebrand factor (VWF) causes von Willebrand disease (VWD), the most frequent inherited bleeding disorder. The laboratory diagnosis of VWD can be difficult as the disease is heterogeneous and an array of assays is required to describe the phenotype. Basic classification of quantitative (type 1 and 3) and qualitative (type 2) VWD variants requires determination of VWF antigenic (VWF:Ag) levels and assaying of VWF ristocetin cofactor (VWF:RCo) activity, determining the capacity of VWF to interact with the platelet GPIb-receptor. Knowing the VWF:RCo activity is essential for identifying, subtyping and monitoring VWD, but the assay is poorly standardized and many protocols do not fulfil the... (More)
The deficiency or abnormal function of von Willebrand factor (VWF) causes von Willebrand disease (VWD), the most frequent inherited bleeding disorder. The laboratory diagnosis of VWD can be difficult as the disease is heterogeneous and an array of assays is required to describe the phenotype. Basic classification of quantitative (type 1 and 3) and qualitative (type 2) VWD variants requires determination of VWF antigenic (VWF:Ag) levels and assaying of VWF ristocetin cofactor (VWF:RCo) activity, determining the capacity of VWF to interact with the platelet GPIb-receptor. Knowing the VWF:RCo activity is essential for identifying, subtyping and monitoring VWD, but the assay is poorly standardized and many protocols do not fulfil the clinical need in all situations. This has led to the development of novel activity assays, independent of ristocetin, with enhanced assay characteristics. Results from the first independent clinical evaluations are promising, showing that they are reliable and suitable for VWD diagnosis. The qualitative type 2 VWF deficiency can be further divided into four different subtypes (A, B, M and N) using specific assays that explore other activities or the size distribution of VWF multimers. These methods are discussed herein. However, in a number of patients it may be difficult to correctly classify the VWD phenotype and genetic analysis may provide the best option to clarify the disorder, through mutation identification.
(Less)
- author
- Castaman, G ; Hillarp, A LU and Goodeve, A
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Blood Coagulation Tests/methods, Genetic Testing, Humans, Ristocetin, von Willebrand Diseases/blood, von Willebrand Factor/chemistry
- in
- Haemophilia
- volume
- 20
- pages
- 6 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000335009800012
- scopus:84899533996
- pmid:24762278
- ISSN
- 1351-8216
- DOI
- 10.1111/hae.12410
- language
- English
- LU publication?
- no
- additional info
- © 2014 John Wiley & Sons Ltd.
- id
- 3403a7d1-4367-42cc-90dd-4a3d1c2a7f6e (old id 4487977)
- date added to LUP
- 2016-04-01 10:37:09
- date last changed
- 2022-08-29 14:48:31
@article{3403a7d1-4367-42cc-90dd-4a3d1c2a7f6e, abstract = {{<p>The deficiency or abnormal function of von Willebrand factor (VWF) causes von Willebrand disease (VWD), the most frequent inherited bleeding disorder. The laboratory diagnosis of VWD can be difficult as the disease is heterogeneous and an array of assays is required to describe the phenotype. Basic classification of quantitative (type 1 and 3) and qualitative (type 2) VWD variants requires determination of VWF antigenic (VWF:Ag) levels and assaying of VWF ristocetin cofactor (VWF:RCo) activity, determining the capacity of VWF to interact with the platelet GPIb-receptor. Knowing the VWF:RCo activity is essential for identifying, subtyping and monitoring VWD, but the assay is poorly standardized and many protocols do not fulfil the clinical need in all situations. This has led to the development of novel activity assays, independent of ristocetin, with enhanced assay characteristics. Results from the first independent clinical evaluations are promising, showing that they are reliable and suitable for VWD diagnosis. The qualitative type 2 VWF deficiency can be further divided into four different subtypes (A, B, M and N) using specific assays that explore other activities or the size distribution of VWF multimers. These methods are discussed herein. However, in a number of patients it may be difficult to correctly classify the VWD phenotype and genetic analysis may provide the best option to clarify the disorder, through mutation identification. </p>}}, author = {{Castaman, G and Hillarp, A and Goodeve, A}}, issn = {{1351-8216}}, keywords = {{Blood Coagulation Tests/methods; Genetic Testing; Humans; Ristocetin; von Willebrand Diseases/blood; von Willebrand Factor/chemistry}}, language = {{eng}}, pages = {{65--70}}, publisher = {{Wiley-Blackwell}}, series = {{Haemophilia}}, title = {{Laboratory aspects of von Willebrand disease : test repertoire and options for activity assays and genetic analysis}}, url = {{http://dx.doi.org/10.1111/hae.12410}}, doi = {{10.1111/hae.12410}}, volume = {{20}}, year = {{2014}}, }